After two "Yes"-votes in the European Parliament’s AGRI and ENVI committees, MEPs confirmed the European Commissions draft Regulation on New Genomic Technologies in plant breeding.
Jazz Pharmaceuticals plc has entered an agreement with Redx Pharma to acquire commercialisation rights to Redx KRAS blockers, which include G12D selective and pan-KRAS molecules.
Spanish Food tech Start-up Heüra Foods secures €40m in Series B financing round to expand product distribution.
Biovian and 3P Biopharmaceuticals have created a new pan-European CDMO, dubbed 3PBIOVIAN.
To improve mRNA product analysis, the Lonza Group Ltd. and Oxford Nanopore Technologies plc. are working together to develop and market a test to assess multiple critical quality attributes of mRNA products
Enterprise Therapeutics Ltd. has raised £26m for the Phase IIa trial of ETD001, a novel cystic fibrosis treatment, with investment led by Panakes Partners and participation from existing investors.
AVT03, a biosimilar candidate for osteoporosis treatment, showed promise in treating bone illnesses, according to results from a pharmacokinetic study by Alvotech SA.
Danish Novozymes A/S and Chr. Hansen Holding A/S have completed their merger, creating a new company named Novonesis.
Following the AGRI Committee of the European Parliament, the lead ENVI Committee has also agreed to relax the rules for the authorisation of NGTs.
Forbion has spearheaded a €75m Series A financing in Norwegian biotech Calluna Pharma. The clinical-stage company resulted from the merger of Oxitope Pharma and Arxx Therapeutics.